Adjuvant epirubicin with or without ifosfamide for adult soft-tissue sarcoma
This randomized study compared the efficacy of epirubicin-based adjuvant chemotherapy on the disease-free interval (DFI) and overall survival of patients with high-risk soft-tissue sarcomas. After curative surgery, 43 of the 88 enrolled patients were assigned to surgery with or without radiotherapy...
Gespeichert in:
| Veröffentlicht in: | American journal of clinical oncology 2002-10, Vol.25 (5), p.468-473 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 473 |
|---|---|
| container_issue | 5 |
| container_start_page | 468 |
| container_title | American journal of clinical oncology |
| container_volume | 25 |
| creator | PETRIOLI, Roberto CORATTI, Andrea PIRTOLI, Luigi FRANCINI, Guido CORREALE, Pierpaolo D'ANIELLO, Carlo GRIMALDI, Luca TANZINI, Gabriello CIVITELLI, Serenella MARSILI, Stefania MESSINESE, Simona MARZOCCA, Giuseppe |
| description | This randomized study compared the efficacy of epirubicin-based adjuvant chemotherapy on the disease-free interval (DFI) and overall survival of patients with high-risk soft-tissue sarcomas. After curative surgery, 43 of the 88 enrolled patients were assigned to surgery with or without radiotherapy and 45 to surgery plus chemotherapy (26 epirubicin, 19 epirubicin + ifosfamide) with or without radiotherapy. The trial closed prematurely because of poor patient accrual. There was a statistical significant difference in the 5-year disease-free survival of the patients receiving adjuvant chemotherapy with or without radiotherapy (69%) and that of those treated with surgery with or without radiotherapy (44%) ( p= 0.01). The 5-year survival of the patients treated with adjuvant chemotherapy with or without radiotherapy was 72% as against 47% of those treated with surgery with or without radiotherapy ( p= 0.06). The power of the study was 0.65 for both the DFI and overall survival. The results of the study suggest a possible advantage of epirubicin-based adjuvant chemotherapy in patients with soft-tissue sarcoma at high risk of relapse. |
| doi_str_mv | 10.1097/00000421-200210000-00009 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72520197</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72520197</sourcerecordid><originalsourceid>FETCH-LOGICAL-c341t-4bebc873bd2ab3753b345009c971b59a91064eb0c95b03479f724712410098c3</originalsourceid><addsrcrecordid>eNpFkMlOwzAQhi0EoqXwCsgXuBm81vGxqtikSlx64BbZji1cZSl2DOLtSWigc5jRjL7ZfgAgwXcEK3mPR-OUIIoxJWOCRqdOwJwIJhEX7O0UzDGVEjHJ6AxcpLQbCLHE8hzMCGWKqWI5B5tVtcufuu2h24eYTbChhV-hf4dd_I1d7mHwXfK6CZWDfijrKtc9TJ3vUR9Syg4mHW3X6Etw5nWd3NUUF2D7-LBdP6PN69PLerVBlnHSI26csYVkpqLaMCmYYVwM11sliRFKK4KX3BlslTCYcam8pFwSyodPVWHZAtwexu5j95Fd6ssmJOvqWreuy6mUVFBMlBzA4gDa2KUUnS_3MTQ6fpcEl6OQ5Z-Q5b-QvyU1tF5PO7JpXHVsnJQbgJsJ0Mnq2kfd2pCOHFOSF4qyH7v6elM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72520197</pqid></control><display><type>article</type><title>Adjuvant epirubicin with or without ifosfamide for adult soft-tissue sarcoma</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>PETRIOLI, Roberto ; CORATTI, Andrea ; PIRTOLI, Luigi ; FRANCINI, Guido ; CORREALE, Pierpaolo ; D'ANIELLO, Carlo ; GRIMALDI, Luca ; TANZINI, Gabriello ; CIVITELLI, Serenella ; MARSILI, Stefania ; MESSINESE, Simona ; MARZOCCA, Giuseppe</creator><creatorcontrib>PETRIOLI, Roberto ; CORATTI, Andrea ; PIRTOLI, Luigi ; FRANCINI, Guido ; CORREALE, Pierpaolo ; D'ANIELLO, Carlo ; GRIMALDI, Luca ; TANZINI, Gabriello ; CIVITELLI, Serenella ; MARSILI, Stefania ; MESSINESE, Simona ; MARZOCCA, Giuseppe</creatorcontrib><description>This randomized study compared the efficacy of epirubicin-based adjuvant chemotherapy on the disease-free interval (DFI) and overall survival of patients with high-risk soft-tissue sarcomas. After curative surgery, 43 of the 88 enrolled patients were assigned to surgery with or without radiotherapy and 45 to surgery plus chemotherapy (26 epirubicin, 19 epirubicin + ifosfamide) with or without radiotherapy. The trial closed prematurely because of poor patient accrual. There was a statistical significant difference in the 5-year disease-free survival of the patients receiving adjuvant chemotherapy with or without radiotherapy (69%) and that of those treated with surgery with or without radiotherapy (44%) ( p= 0.01). The 5-year survival of the patients treated with adjuvant chemotherapy with or without radiotherapy was 72% as against 47% of those treated with surgery with or without radiotherapy ( p= 0.06). The power of the study was 0.65 for both the DFI and overall survival. The results of the study suggest a possible advantage of epirubicin-based adjuvant chemotherapy in patients with soft-tissue sarcoma at high risk of relapse.</description><identifier>ISSN: 0277-3732</identifier><identifier>EISSN: 1537-453X</identifier><identifier>DOI: 10.1097/00000421-200210000-00009</identifier><identifier>PMID: 12393986</identifier><identifier>CODEN: AJCODI</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Antibiotics, Antineoplastic - therapeutic use ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Chemotherapy ; Chemotherapy, Adjuvant ; Combined Modality Therapy ; Epirubicin - administration & dosage ; Epirubicin - therapeutic use ; Female ; Humans ; Ifosfamide - administration & dosage ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Sarcoma - drug therapy ; Sarcoma - radiotherapy ; Sarcoma - surgery ; Survival Analysis</subject><ispartof>American journal of clinical oncology, 2002-10, Vol.25 (5), p.468-473</ispartof><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c341t-4bebc873bd2ab3753b345009c971b59a91064eb0c95b03479f724712410098c3</citedby><cites>FETCH-LOGICAL-c341t-4bebc873bd2ab3753b345009c971b59a91064eb0c95b03479f724712410098c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13974892$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12393986$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>PETRIOLI, Roberto</creatorcontrib><creatorcontrib>CORATTI, Andrea</creatorcontrib><creatorcontrib>PIRTOLI, Luigi</creatorcontrib><creatorcontrib>FRANCINI, Guido</creatorcontrib><creatorcontrib>CORREALE, Pierpaolo</creatorcontrib><creatorcontrib>D'ANIELLO, Carlo</creatorcontrib><creatorcontrib>GRIMALDI, Luca</creatorcontrib><creatorcontrib>TANZINI, Gabriello</creatorcontrib><creatorcontrib>CIVITELLI, Serenella</creatorcontrib><creatorcontrib>MARSILI, Stefania</creatorcontrib><creatorcontrib>MESSINESE, Simona</creatorcontrib><creatorcontrib>MARZOCCA, Giuseppe</creatorcontrib><title>Adjuvant epirubicin with or without ifosfamide for adult soft-tissue sarcoma</title><title>American journal of clinical oncology</title><addtitle>Am J Clin Oncol</addtitle><description>This randomized study compared the efficacy of epirubicin-based adjuvant chemotherapy on the disease-free interval (DFI) and overall survival of patients with high-risk soft-tissue sarcomas. After curative surgery, 43 of the 88 enrolled patients were assigned to surgery with or without radiotherapy and 45 to surgery plus chemotherapy (26 epirubicin, 19 epirubicin + ifosfamide) with or without radiotherapy. The trial closed prematurely because of poor patient accrual. There was a statistical significant difference in the 5-year disease-free survival of the patients receiving adjuvant chemotherapy with or without radiotherapy (69%) and that of those treated with surgery with or without radiotherapy (44%) ( p= 0.01). The 5-year survival of the patients treated with adjuvant chemotherapy with or without radiotherapy was 72% as against 47% of those treated with surgery with or without radiotherapy ( p= 0.06). The power of the study was 0.65 for both the DFI and overall survival. The results of the study suggest a possible advantage of epirubicin-based adjuvant chemotherapy in patients with soft-tissue sarcoma at high risk of relapse.</description><subject>Antibiotics, Antineoplastic - therapeutic use</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Chemotherapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>Combined Modality Therapy</subject><subject>Epirubicin - administration & dosage</subject><subject>Epirubicin - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Ifosfamide - administration & dosage</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Sarcoma - drug therapy</subject><subject>Sarcoma - radiotherapy</subject><subject>Sarcoma - surgery</subject><subject>Survival Analysis</subject><issn>0277-3732</issn><issn>1537-453X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkMlOwzAQhi0EoqXwCsgXuBm81vGxqtikSlx64BbZji1cZSl2DOLtSWigc5jRjL7ZfgAgwXcEK3mPR-OUIIoxJWOCRqdOwJwIJhEX7O0UzDGVEjHJ6AxcpLQbCLHE8hzMCGWKqWI5B5tVtcufuu2h24eYTbChhV-hf4dd_I1d7mHwXfK6CZWDfijrKtc9TJ3vUR9Syg4mHW3X6Etw5nWd3NUUF2D7-LBdP6PN69PLerVBlnHSI26csYVkpqLaMCmYYVwM11sliRFKK4KX3BlslTCYcam8pFwSyodPVWHZAtwexu5j95Fd6ssmJOvqWreuy6mUVFBMlBzA4gDa2KUUnS_3MTQ6fpcEl6OQ5Z-Q5b-QvyU1tF5PO7JpXHVsnJQbgJsJ0Mnq2kfd2pCOHFOSF4qyH7v6elM</recordid><startdate>20021001</startdate><enddate>20021001</enddate><creator>PETRIOLI, Roberto</creator><creator>CORATTI, Andrea</creator><creator>PIRTOLI, Luigi</creator><creator>FRANCINI, Guido</creator><creator>CORREALE, Pierpaolo</creator><creator>D'ANIELLO, Carlo</creator><creator>GRIMALDI, Luca</creator><creator>TANZINI, Gabriello</creator><creator>CIVITELLI, Serenella</creator><creator>MARSILI, Stefania</creator><creator>MESSINESE, Simona</creator><creator>MARZOCCA, Giuseppe</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20021001</creationdate><title>Adjuvant epirubicin with or without ifosfamide for adult soft-tissue sarcoma</title><author>PETRIOLI, Roberto ; CORATTI, Andrea ; PIRTOLI, Luigi ; FRANCINI, Guido ; CORREALE, Pierpaolo ; D'ANIELLO, Carlo ; GRIMALDI, Luca ; TANZINI, Gabriello ; CIVITELLI, Serenella ; MARSILI, Stefania ; MESSINESE, Simona ; MARZOCCA, Giuseppe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c341t-4bebc873bd2ab3753b345009c971b59a91064eb0c95b03479f724712410098c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Antibiotics, Antineoplastic - therapeutic use</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Chemotherapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>Combined Modality Therapy</topic><topic>Epirubicin - administration & dosage</topic><topic>Epirubicin - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Ifosfamide - administration & dosage</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Sarcoma - drug therapy</topic><topic>Sarcoma - radiotherapy</topic><topic>Sarcoma - surgery</topic><topic>Survival Analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>PETRIOLI, Roberto</creatorcontrib><creatorcontrib>CORATTI, Andrea</creatorcontrib><creatorcontrib>PIRTOLI, Luigi</creatorcontrib><creatorcontrib>FRANCINI, Guido</creatorcontrib><creatorcontrib>CORREALE, Pierpaolo</creatorcontrib><creatorcontrib>D'ANIELLO, Carlo</creatorcontrib><creatorcontrib>GRIMALDI, Luca</creatorcontrib><creatorcontrib>TANZINI, Gabriello</creatorcontrib><creatorcontrib>CIVITELLI, Serenella</creatorcontrib><creatorcontrib>MARSILI, Stefania</creatorcontrib><creatorcontrib>MESSINESE, Simona</creatorcontrib><creatorcontrib>MARZOCCA, Giuseppe</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>PETRIOLI, Roberto</au><au>CORATTI, Andrea</au><au>PIRTOLI, Luigi</au><au>FRANCINI, Guido</au><au>CORREALE, Pierpaolo</au><au>D'ANIELLO, Carlo</au><au>GRIMALDI, Luca</au><au>TANZINI, Gabriello</au><au>CIVITELLI, Serenella</au><au>MARSILI, Stefania</au><au>MESSINESE, Simona</au><au>MARZOCCA, Giuseppe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adjuvant epirubicin with or without ifosfamide for adult soft-tissue sarcoma</atitle><jtitle>American journal of clinical oncology</jtitle><addtitle>Am J Clin Oncol</addtitle><date>2002-10-01</date><risdate>2002</risdate><volume>25</volume><issue>5</issue><spage>468</spage><epage>473</epage><pages>468-473</pages><issn>0277-3732</issn><eissn>1537-453X</eissn><coden>AJCODI</coden><abstract>This randomized study compared the efficacy of epirubicin-based adjuvant chemotherapy on the disease-free interval (DFI) and overall survival of patients with high-risk soft-tissue sarcomas. After curative surgery, 43 of the 88 enrolled patients were assigned to surgery with or without radiotherapy and 45 to surgery plus chemotherapy (26 epirubicin, 19 epirubicin + ifosfamide) with or without radiotherapy. The trial closed prematurely because of poor patient accrual. There was a statistical significant difference in the 5-year disease-free survival of the patients receiving adjuvant chemotherapy with or without radiotherapy (69%) and that of those treated with surgery with or without radiotherapy (44%) ( p= 0.01). The 5-year survival of the patients treated with adjuvant chemotherapy with or without radiotherapy was 72% as against 47% of those treated with surgery with or without radiotherapy ( p= 0.06). The power of the study was 0.65 for both the DFI and overall survival. The results of the study suggest a possible advantage of epirubicin-based adjuvant chemotherapy in patients with soft-tissue sarcoma at high risk of relapse.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>12393986</pmid><doi>10.1097/00000421-200210000-00009</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0277-3732 |
| ispartof | American journal of clinical oncology, 2002-10, Vol.25 (5), p.468-473 |
| issn | 0277-3732 1537-453X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72520197 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Antibiotics, Antineoplastic - therapeutic use Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Chemotherapy Chemotherapy, Adjuvant Combined Modality Therapy Epirubicin - administration & dosage Epirubicin - therapeutic use Female Humans Ifosfamide - administration & dosage Male Medical sciences Middle Aged Pharmacology. Drug treatments Sarcoma - drug therapy Sarcoma - radiotherapy Sarcoma - surgery Survival Analysis |
| title | Adjuvant epirubicin with or without ifosfamide for adult soft-tissue sarcoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T07%3A09%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adjuvant%20epirubicin%20with%20or%20without%20ifosfamide%20for%20adult%20soft-tissue%20sarcoma&rft.jtitle=American%20journal%20of%20clinical%20oncology&rft.au=PETRIOLI,%20Roberto&rft.date=2002-10-01&rft.volume=25&rft.issue=5&rft.spage=468&rft.epage=473&rft.pages=468-473&rft.issn=0277-3732&rft.eissn=1537-453X&rft.coden=AJCODI&rft_id=info:doi/10.1097/00000421-200210000-00009&rft_dat=%3Cproquest_cross%3E72520197%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72520197&rft_id=info:pmid/12393986&rfr_iscdi=true |